CN112387980A - Nano gold particle, drug carrier containing nano gold particle, preparation method of nano gold particle and application of nano gold particle - Google Patents
Nano gold particle, drug carrier containing nano gold particle, preparation method of nano gold particle and application of nano gold particle Download PDFInfo
- Publication number
- CN112387980A CN112387980A CN201910765726.7A CN201910765726A CN112387980A CN 112387980 A CN112387980 A CN 112387980A CN 201910765726 A CN201910765726 A CN 201910765726A CN 112387980 A CN112387980 A CN 112387980A
- Authority
- CN
- China
- Prior art keywords
- solution
- nano
- gold
- gold nanoparticles
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000010931 gold Substances 0.000 title claims abstract description 161
- 229910052737 gold Inorganic materials 0.000 title claims abstract description 161
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 title claims abstract description 140
- 239000002245 particle Substances 0.000 title claims abstract description 96
- 238000002360 preparation method Methods 0.000 title claims abstract description 49
- 239000003937 drug carrier Substances 0.000 title claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 40
- 239000003638 chemical reducing agent Substances 0.000 claims abstract description 20
- 239000003223 protective agent Substances 0.000 claims abstract description 18
- 238000006243 chemical reaction Methods 0.000 claims abstract description 16
- 238000002156 mixing Methods 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000002105 nanoparticle Substances 0.000 claims description 98
- 238000000034 method Methods 0.000 claims description 20
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical group OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 10
- 229940067606 lecithin Drugs 0.000 claims description 10
- 235000010445 lecithin Nutrition 0.000 claims description 10
- 239000000787 lecithin Substances 0.000 claims description 10
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 10
- 229960000401 tranexamic acid Drugs 0.000 claims description 10
- 239000002537 cosmetic Substances 0.000 claims description 9
- 102000008186 Collagen Human genes 0.000 claims description 8
- 108010035532 Collagen Proteins 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 5
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 229940074391 gallic acid Drugs 0.000 claims description 5
- 235000004515 gallic acid Nutrition 0.000 claims description 5
- 229920002674 hyaluronan Polymers 0.000 claims description 5
- 229960003160 hyaluronic acid Drugs 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229960005188 collagen Drugs 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 109
- 239000000523 sample Substances 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 16
- 239000012488 sample solution Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- 238000006722 reduction reaction Methods 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 230000036632 reaction speed Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F9/00—Making metallic powder or suspensions thereof
- B22F9/16—Making metallic powder or suspensions thereof using chemical processes
- B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
- B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Composite Materials (AREA)
- Manufacturing & Machinery (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Manufacture Of Metal Powder And Suspensions Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The application provides a preparation method of nano gold particles, a drug carrier containing the nano gold particles and application of the nano gold particles. The preparation method of the nano gold particles comprises the following steps: (a) providing chloroauric acid and a protective agent, wherein the purity of the chloroauric acid is more than 99.99%; (b) dissolving the chloroauric acid and the protective agent in water to form an initial solution; and (c) adding a reducing agent into the initial solution for mixing reaction, wherein the reducing agent reduces the chloroauric acid to form nano gold particles. By the preparation method of the nano-gold particles and the nano-gold particles prepared by the preparation method, the problem of uneven particle size of the nano-gold particles prepared by the existing preparation method of the nano-gold particles can be solved.
Description
Technical Field
The present invention relates to a gold nanoparticle, a drug carrier comprising the same, a method for preparing the same, and uses thereof, and more particularly, to a gold nanoparticle prepared by a method for preparing a gold nanoparticle having a uniform particle size.
Background
The nano gold particles are one of nano metal particles commonly used in the medical field, can be applied to biological detection, sample analysis, heat treatment and computer tomography image, and can also be used as a drug carrier for carrying drugs. The commonly used methods for preparing gold nanoparticles at present are mainly divided into chemical methods and physical methods, the common chemical methods include redox method, photochemical method or electrochemical method, and the common physical methods include gas vapor method and laser ablation method.
Disclosure of Invention
However, when the nanogold particles are prepared by the conventional method for preparing nanogold particles, the nanogold particles are generally prepared using a gold-containing compound having a purity of less than 99.9% (for example, chloroauric acid) as a main raw material, and the nanogold particles prepared using a gold-containing compound having a purity of less than 99.9% show a phenomenon in which the nanogold particles have non-uniform particle diameters, as shown in fig. 24. When the nano gold particles are used as a drug carrier, if the particle size of the nano gold particles is not uniform, the content of the drug carried by each nano gold particle is also inconsistent, so that the release time and the drug dosage cannot be accurately controlled. Therefore, the problem to be solved is that the particle size of the nano gold particles prepared by the existing nano gold particle preparation method is not uniform.
The present application aims to solve the above problems and provide a method for preparing gold nanoparticles, comprising the following steps: (a) providing chloroauric acid and a protective agent, wherein the purity of the chloroauric acid is more than 99.99%; (b) dissolving the chloroauric acid and the protective agent in water and mixing to form an initial solution; and (c) adding a reducing agent into the initial solution for mixing reaction, wherein the reducing agent reduces the chloroauric acid to form nano gold particles.
The preparation method as described above, wherein the molar ratio of the chloroauric acid to the reducing agent is 1:5 to 1: 10. .
In the above preparation method, the reducing agent is gallic acid, tranexamic acid or vitamin C.
In the preparation method, the protective agent is lecithin, collagen or hyaluronic acid.
The preparation method as described above, wherein the step (b) and the step (c) are both performed in an environment of 4-25 ℃.
The above-mentioned preparation method, the purity of the chloroauric acid is above 99.999%.
To achieve the above and other objects, the present application provides a gold nanoparticle prepared by the above-mentioned method.
To achieve the above and other objects, the present application provides a drug carrier, comprising a plurality of gold nanoparticles, wherein more than 90% of the gold nanoparticles have a particle size of about 50-70 nm.
To achieve the above and other objects, the present application provides a use of the above-mentioned gold nanoparticles for preparing a pharmaceutical carrier, a cosmetic or a cosmetic.
The use as described above, wherein the cosmetic is a composite of gold nanoparticles and collagen.
By the preparation method and the nano-gold particles prepared by the preparation method, the problem of uneven particle size of the nano-gold particles prepared by the existing nano-gold particle preparation method can be solved.
Drawings
FIG. 1 is a color chart of the appearance of a sample solution of example 1 of the present application after reaction for two hours.
Fig. 2 is a color chart of the appearance of the sample solution of example 1 of the present application after twenty-four hours of reaction.
FIG. 3 is a graph showing an absorbance distribution of a sample solution of example 1 of the present application.
Fig. 4 is an enlarged view of the gold nanoparticles of example 1 of the present application.
Fig. 5 is an enlarged view of the gold nanoparticles of example 1 of the present application.
Fig. 6 is an enlarged view of the gold nanoparticles of example 1 of the present application.
Fig. 7 is a graph showing the result of the cytotoxicity test of the gold nanoparticles of example 1 of the present application.
FIG. 8 is a color chart of the appearance of a sample solution of example 2 of the present application after one hour of reaction.
Fig. 9 is a color chart of the appearance of the sample solution of example 2 of the present application after twenty-four hours of reaction.
FIG. 10 is a graph showing an absorbance distribution of a sample solution of example 2 of the present application.
Fig. 11 is an enlarged view of the gold nanoparticles of example 2 of the present application.
Fig. 12 is an enlarged view of the gold nanoparticles of example 2 of the present application.
Fig. 13 is an enlarged view of the gold nanoparticles of example 2 of the present application.
FIG. 14 is a color chart of the appearance of a sample solution of example 3 of the present application after reaction for one hour.
Fig. 15 is a color chart of the appearance of the sample solution of example 3 of the present application after one hundred and twenty hours of reaction.
FIG. 16 is an absorbance profile of a sample solution of example 3 of the present application.
Fig. 17 is an enlarged view of gold nanoparticles of example 3 of the present application.
Fig. 18 is an enlarged view of gold nanoparticles of example 3 of the present application.
FIG. 19 is a color chart of an appearance of a sample solution of example 4 of the present application after reaction for one minute.
Fig. 20 is a color chart of the appearance of a sample solution of example 4 of the present application after twenty-four hours of reaction.
FIG. 21 is a graph showing an absorbance distribution of a sample solution of example 4 of the present application.
FIG. 22 is an absorbance profile of a sample solution of example 4 of the present application.
Fig. 23 is an enlarged view of gold nanoparticles of example 4 of the present application.
Fig. 24 is an enlarged view of gold nanoparticles prepared by a conventional gold nanoparticle preparation method.
Detailed Description
For a fuller understanding of the objects, features and advantages of the present application, reference should be made to the following detailed description taken in conjunction with the accompanying drawings, in which:
the preparation method of the nano gold particles comprises the following steps:
chloroauric acid (Chloroauric acid) with a purity of 99.99% or more and a protective agent are provided. And then, dissolving the chloroauric acid and the protective agent in water, and uniformly mixing to form an initial solution. And finally, adding a reducing agent into the initial solution for mixing reaction, wherein the reducing agent reduces the chloroauric acid to form nano gold particles.
The purity of the chloroauric acid can be 99.990%, 99.991%, 99.992%, 99.993%, 99.994%, 99.995%, 99.996%, 99.997%, 99.998%, 99.999%, even 99.9999% or higher, but the purity of the chloroauric acid only needs to be 99.99% or higher, and is not limited to the specific values.
The molar ratio of the chloroauric acid to the reducing agent may preferably be 1:5 to 1:10, for example: 1:5, 1:6, 1:7, 1:8, 1:9, 1: 10. However, in other embodiments, the specific values are not limited to the above specific values.
The reducing agent is preferably gallic acid (gallic acid), Tranexamic acid (Tranexamic acid) or vitamin C. However, in other embodiments, a reducing agent having similar properties to the foregoing reducing agent may be selected, but not limited thereto.
The protective agent is used for being adsorbed on the surface of the nano-gold particles, stabilizing the nano-gold particles, avoiding mutual aggregation of the nano-gold particles and limiting the particle size of the nano-gold particles, and the protective agent is preferably Lecithin (Lecithin), Collagen (Collagen) or Hyaluronic acid (Hyaluronic acid). However, in other embodiments, a protecting agent having similar properties to the protecting agent described above may be selected, but not limited thereto.
The preparation of the gold nanoparticles is preferably carried out at 4-25 deg.C, and the temperature of the preparation process can be 4 deg.C, 5 deg.C, 6 deg.C, 7 deg.C, 8 deg.C, 9 deg.C, 10 deg.C, 11 deg.C, 12 deg.C, 13 deg.C, 14 deg.C, 15 deg.C, 16 deg.C, 17 deg.C, 18 deg.C, 19 deg.C, 20 deg.C, 21 deg.C, 22 deg.C. However, in other embodiments, the specific values are not limited to the above specific values.
Preparation of gold nanoparticles of example 1:
in this example 1, the gold nanoparticle-containing solution samples 1 to 3 were prepared by the above-described gold nanoparticle preparation method, and the specific preparation process was as follows.
First, the desired gold nanoparticle preparation materials for solution samples 1-3, and the volumes of each material are provided as listed in table 1 below. In this example 1, a tranexamic acid solution (from chemical materials, Inc.) was used as the reducing agent, a lecithin solution (from Chen product, Inc.) was used as the protective agent, and the chloroauric acid in the chloroauric acid solution was 99.999% pure (from Sigma Aldrich, Inc.).
Since the preparation processes of samples 1 to 3 are substantially the same, the reaction of sample 2 is performed in an environment of 25 ℃ as described below by taking sample 2 as an example. The chloroauric acid solution and the lecithin solution in the sample 2 are provided, and then deionized water is added into the chloroauric acid solution and the lecithin solution in the sample 2 to be mixed to form an initial solution (in the sample 1, the chloroauric acid and the lecithin are fully dissolved in the chloroauric acid solution and the lecithin solution in the sample 1 to be mixed to form the initial solution). Then, the tranexamic acid solution of the sample 2 is added to the initial solution of the sample 2 to mix and react, so that the tranexamic acid reduces the chloroauric acid into the nano gold particles.
Table 1: volume of each component of samples 1-3
As shown in fig. 1, after the solution samples 1-3 are subjected to the reduction reaction for two hours, the solution samples 1 and 2 are light purple, which means that a small amount of nano-gold particles are formed at this time, and the solution sample 3 is colorless, which means that no nano-gold particles are formed at this time. As shown in fig. 2, after twenty-four hours of the reduction reaction of the solution samples 1 to 3, it can be seen that the solution samples 1 to 3 are all dark purple, i.e., the solution samples 1 to 3 contain a large amount of nano-gold particles, but the solution sample 3 is lighter in color than the solution samples 1 and 2.
After the reduction reaction of the solution samples 1-3 is carried out for forty-eight hours, the absorption value of the solution samples 1-3 is measured by a spectrophotometer, and the result is shown in FIG. 3, wherein the solution samples 1-3 have the highest absorption value between the wavelength of 540 and 580nm, and the wavelength of 540 and 580nm is the wavelength of the gold nanoparticles.
Referring again to fig. 4, fig. 4 is an enlarged view of the gold nanoparticles in the solution sample 1 observed under an electron microscope at a magnification of 250000 times, and it can be seen from fig. 4 that the size of the gold nanoparticles in the solution sample 1 is substantially uniform in size. More than 90% of the gold nanoparticles in the sample solution 1 have a size of about 50-70 nm. Also, the gold nanoparticles in the solution sample 1 have a uniform shape, mainly taking a hexagonal or circular shape.
In addition, if the particle size of the gold nanoparticles is too large, the gold nanoparticles are not easily discharged out of the cells, if the particle size of the gold nanoparticles is too small, the gold nanoparticles may not exert their effects, and if the gold nanoparticles are triangular or quadrangular in shape, the gold nanoparticles may be easily aggregated to form a crystal column and cause a precipitation reaction. The gold nanoparticles in the solution sample 1 have a uniform particle size and are substantially hexagonal or circular, so that various problems caused by the gold nanoparticles having a particle size that is too large or too small or the shape thereof can be avoided.
Referring again to fig. 5, fig. 5 is an enlarged view of the gold nanoparticles in the solution sample 2 observed under an electron microscope at a magnification of 250000 times, and it can be seen from fig. 5 that the size of the gold nanoparticles in the solution sample 2 is also substantially uniform in size. More than 90% of the gold nanoparticles in sample 2 of the solution also have a size of approximately 50-70 nm.
Referring to fig. 6 again, fig. 6 is an enlarged view of the gold nanoparticles in the solution sample 3 observed under an electron microscope at a magnification of 250000 times, and it can be seen from fig. 6 that the gold nanoparticles in the solution sample 3 have a less uniform particle size, and thus the particle size of the gold nanoparticles in the solution sample 3 is not uniform compared to the particle size of the gold nanoparticles in the solution samples 1 and 2. However, the particle size of the gold nanoparticles in the solution sample 3 is still uniform compared to the particle size of the gold nanoparticles synthesized by the existing preparation method.
As can be seen from the comparison of fig. 4 to 6, in the above-mentioned method for preparing gold nanoparticles, gold nanoparticles having a substantially uniform particle size can be obtained by adjusting the molar ratio of chloroauric acid to tranexamic acid to 1:5, and by adjusting the molar ratio of chloroauric acid to tranexamic acid to 1:10, even to 1: 20. However, in other embodiments, the gold nanoparticles can be prepared without depending on the molar ratio of chloroauric acid to tranexamic acid, and the gold nanoparticles having a more uniform particle size than the gold nanoparticles synthesized by the conventional preparation method can be prepared by the aforementioned gold nanoparticle preparation method.
Cytotoxicity assay of gold nanoparticles of example 1:
first, in a preparation method of preparing the aforementioned gold nanoparticles of example 1, solution samples 1 to 3 were prepared, and the solution samples 1 to 3 were reacted at room temperature for 24 hours. Simultaneously, four 6-well plates were prepared, and 1ml of NIH/3T3 cell culture medium (cultured in DMEM medium containing NIH/3T3 cells at a concentration of 1X 10) was injected into each of three wells of each 6-well plate5Cells/ml), and 1ml of ea.hy926 cell culture solution (cultured in DMEM medium containing NIH/3T3 cells at a concentration of 1 × 10) was injected into each of the other three wells of the four 6-well plates to which no cell culture solution was added5Cells/ml). NIH/3T3 cells were a mouse embryonic fibroblast, ea.hy926 cells were an endothelial cell line, and NIH/3T3 cells and ea.hy926 cells were used in this experiment to test whether the gold nanoparticles in the solution samples 1-3 of example 1 were cytotoxic.
Next, 10 μ l of the solution sample 1 was added to each of the six wells containing the cell culture solution of the first 6-well plate (three wells containing NIH/3T3 cell culture solution and the other three wells containing ea.hy926 cell culture solution) as an experimental group 1, and the solution samples 2 and 3 were added to each of the second 6-well plate and the third 6-well plate as experimental groups 2 to 4, and the solution containing the gold nanoparticles was not added to the fourth 6-well plate as a control group, in the manner described above for the solution sample 1 added to the first 6-well plate.
Finally, the 6-well plates of the experimental groups 1 to 3 and the control group were placed in a cell incubator, incubated at 37 ℃, and after incubation for 24 hours, the 6-well plates of the experimental groups 1 to 3 and the control group were removed from the cell incubator, and an MTT test was performed using a tetramethylazonium salt solution (MTT,3- (4, 5-dimethylthiozoli-2-yl) -2,5-diphenyltetrazolium bromide) to test the activity of the cells in the experimental groups 1 to 3 and the control group, and the average cell survival rates of the experimental groups 1 to 3 and the control group were calculated based on the MTT test results.
FIG. 7 shows the results of the cell survival assay of nanogold particles, and it can be seen from FIG. 7 that the numbers of NIH/3T3 cells in the experimental groups 1 to 3, to which the solution samples 1 to 3 were added, and the numbers of NIH/3T3 cells in the control group, to which the solution samples 1 to 3 were not added, were increased compared to the numbers of NIH/3T3 cells in the control group, after 24 hours of incubation; and the numbers of EA.hy926 cells of experimental groups 1-3 were only slightly lower than those of the control group. Therefore, the gold nanoparticles prepared by the method of example 1 are highly biocompatible and have no biotoxicity.
Preparation of gold nanoparticles of example 2:
in this example 2, the gold nanoparticle-containing solution samples 4 to 6 were prepared by the above-described gold nanoparticle preparation method, and the specific preparation process was as follows.
First, the desired gold nanoparticle preparation materials for solution samples 4-6, and the volumes of each material are provided as listed in table 2 below. In this embodiment 2, the reducing agent is a gallic acid solution, the protecting agent is a lecithin solution, and the purity of chloroauric acid in the chloroauric acid solution is 99.999%.
Then, the materials for preparing the solution samples 4 to 6 were sequentially mixed and reacted according to the method for preparing gold nanoparticles of example 1, and the gold nanoparticles were reduced.
Table 2: volume of each component of samples 4-6
After the solution samples 4-6 are subjected to the reduction reaction for one hour, as shown in fig. 8, the solution samples 4, 6 are light purple, which means that a small amount of nano gold particles are formed. The solution sample 5 is light red, which means that a small amount of nano-gold particles are formed at this time, but the nano-gold particles in the solution sample 5 are smaller than those in the solution samples 4 and 6.
After twenty-four hours of the reduction reaction of the solution samples 4 to 6, as shown in FIG. 9, it can be seen that the color of the solution samples 4 to 6 was not significantly changed.
After the reduction reaction of the solution sample 4-6 is carried out for forty-eight hours, the absorbance of the solution sample 4-6 is measured by a spectrophotometer, and the result is shown in fig. 10, where the solution sample 4-6 has the highest absorbance between the wavelength of 540 and 580nm, the wavelength of 540 and 580nm is the wavelength of the nanogold particles, and the solution sample 7 has no obvious absorbance peak at the wavelength of 540 and 580nm, which indicates that the nanogold particles are not generated in the solution sample 7.
Referring again to fig. 11-13, fig. 11-13 are enlarged views of the gold nanoparticles in the solution samples 4-6 observed by an electron microscope at a magnification of 200000 times, respectively, and it can be seen from fig. 11-13 that the gold nanoparticles in the solution samples 4-6 have a substantially uniform size. More than 90% of the gold nanoparticles in the solution sample 4-6 have a size of about 50-70 nm.
Preparation of gold nanoparticles of example 3:
in example 3, the gold nanoparticle-containing solution samples 7 and 8 were prepared by the above-described gold nanoparticle preparation method, and the specific preparation process was as follows.
First, the desired gold nanoparticle preparation materials for the solution samples 7 and 8 are provided, and the desired gold nanoparticle preparation materials for the solution samples 7 and 8 and the volumes of the respective materials are listed in table 3 below. In this example 3, vitamin C is used as the reducing agent, collagen is used as the protective agent, and the purity of chloroauric acid in the chloroauric acid solution is 99.999%.
Then, the materials for preparing the solution samples 7 and 8 were mixed and reacted in sequence according to the method for preparing gold nanoparticles in example 1, and gold nanoparticles were reduced.
Table 3: volume of each component of samples 7, 8
The solution samples 7, 8 were colorless after the reduction reaction had proceeded for one hour (as shown in fig. 14), until the solution samples 7, 8 were slightly purplish in color after the reduction reaction had proceeded for one hundred twenty hours (as shown in fig. 15).
After the solution samples 7 and 8 are subjected to the reduction reaction for one hundred twenty hours, the absorbance values of the solution samples 7 and 8 are measured by a spectrophotometer, and as shown in fig. 16, the solution samples 7 and 8 have absorbance values of about 0.05-0.06 in the wavelength range of 540-. In addition, the reaction of this embodiment 3 is performed in an environment of 4 ℃, so that the reaction speed of reducing the gold nanoparticles in the solution samples 7 and 8 is also slow due to the low ambient temperature, and when the reaction speed is slow, the reaction helps to make the particle diameters of the gold nanoparticles reduced in the solution samples 7 and 8 more uniform. Therefore, when the gold nanoparticles in the solution samples 7 and 8 are observed under an electron microscope at a magnification of 250000 times, as shown in fig. 17 and 18, 90% or more of the gold nanoparticles in the solution samples 7 and 8 have a size of about 50 to 70nm, and the gold nanoparticles in the solution samples 7 and 8 have a more uniform particle size than the gold nanoparticles in the solution samples 1 to 7.
Preparation of gold nanoparticles of example 4:
in this example 4, samples 9 to 16 of the gold nanoparticle-containing solution were prepared by the above-described gold nanoparticle preparation method, and the specific preparation process was as follows.
First, the desired gold nanoparticle preparation materials for solution samples 9-16, and the volumes of each material are provided as listed in table 4 below. In this embodiment 4, vitamin C is used as the reducing agent, hyaluronic acid is used as the protecting agent, and the purity of chloroauric acid in the chloroauric acid solution is 99.999%.
Then, the materials for preparing the solution samples 9 to 16 were sequentially mixed and reacted according to the method for preparing gold nanoparticles of example 1, and the gold nanoparticles were reduced.
Table 4: volume of each component of samples 9-16
After one minute of the reduction reaction of the solution sample 9-16, as shown in FIG. 19, the solution sample 9-11 is pink or light purple, which means that a small amount of gold nanoparticles are formed. The solution samples 12-16 were dark blue, indicating that gold nanoparticles were also formed.
Twenty-four hours after the reduction reaction of the solution samples 9-16, as shown in fig. 20, the original color of the solution samples 9-11 becomes dark, and the solution samples 12-16 turn dark purple, which means that more nano gold particles are generated.
When the solution samples 9-16 were subjected to the reduction reaction for ninety-six hours, the absorbance of the solution samples 9-16 was measured by a spectrophotometer, and as a result, as shown in FIGS. 21 and 22, the peaks of the solution samples 9-16 were located substantially in the range of 540-580nm, i.e., there were gold nanoparticles generated in the solution samples 9-16. When observed under an electron microscope at magnification of 200000-250000 times, the results are shown in FIG. 23, in which the sizes of the gold nanoparticles in the solution samples 9-16 are substantially uniform. More than 90% of the gold nanoparticles in the solution sample 9-16 have a size of about 50-70 nm.
Application of the gold nanoparticles of this example:
because the nano gold particles with uniform particle size can be prepared by the nano gold particle preparation method, when the nano gold particles prepared in the embodiment are used as a drug carrier, the content of drugs carried by each nano gold particle is relatively consistent, so that the nano gold particles prepared in the embodiment can be prepared into the drug carrier, the drug carrier comprises a plurality of nano gold particles, the particle size of more than 90% of the nano gold particles in the drug carrier is about 50-70nm, namely, most of the nano gold particles in the drug carrier have consistent particle size, and the drug carrier can accurately control the release time of the drugs and the drug administration dosage.
In addition, the nano-gold particles prepared in the above embodiments may be used for manufacturing a drug carrier, or may be used for manufacturing a cosmetic or a cosmetic, for example, the nano-gold particles prepared in the above embodiments may be combined with collagen to prepare a cosmetic.
Compared with the nano gold particles prepared by the existing nano gold particle preparation method, the nano gold particles prepared by the nano gold particle preparation method of the embodiment have more uniform particle size. Therefore, by the preparation method and the nano-gold particles prepared by the preparation method, the problem of uneven particle size of the nano-gold particles prepared by the existing nano-gold particle preparation method can be solved.
The present application has been disclosed in the foregoing as preferred embodiments, however, it should be understood by those skilled in the art that the embodiments are merely illustrative of the present application and should not be construed as limiting the scope of the present application. It is noted that equivalent variations and substitutions for the embodiments are intended to be included within the scope of the present application. Therefore, the protection scope of the present application shall be subject to the scope defined by the claims.
Claims (10)
1. A method for preparing gold nanoparticles is characterized by comprising the following steps:
(a) providing chloroauric acid and a protective agent, wherein the purity of the chloroauric acid is more than 99.99%;
(b) dissolving the chloroauric acid and the protective agent in water and mixing to form an initial solution; and
(c) and adding a reducing agent into the initial solution for mixing reaction, wherein the reducing agent reduces the chloroauric acid to form nano gold particles.
2. The production method according to claim 1, wherein the molar ratio of the chloroauric acid to the reducing agent is 1:5 to 1: 10.
3. The method according to claim 1, wherein the reducing agent is gallic acid, tranexamic acid or vitamin C.
4. The method of claim 1, wherein the protective agent is lecithin, collagen, or hyaluronic acid.
5. The method of claim 1, wherein the steps (b) and (c) are performed in an environment of 4-25 ℃.
6. The method according to claim 1, wherein the purity of the chloroauric acid is 99.999% or more.
7. Gold nanoparticles, characterized by being produced by the production method according to any one of claims 1 to 6.
8. A drug carrier is characterized by comprising a plurality of nano gold particles, wherein more than 90% of the nano gold particles have the particle size of about 50-70 nm.
9. Use of the gold nanoparticles according to any one of claims 1 to 6 for the preparation of a pharmaceutical carrier, a cosmetic or a cosmetic product.
10. The use according to claim 9, wherein the cosmetic is a composite of gold nanoparticles and collagen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910765726.7A CN112387980A (en) | 2019-08-19 | 2019-08-19 | Nano gold particle, drug carrier containing nano gold particle, preparation method of nano gold particle and application of nano gold particle |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910765726.7A CN112387980A (en) | 2019-08-19 | 2019-08-19 | Nano gold particle, drug carrier containing nano gold particle, preparation method of nano gold particle and application of nano gold particle |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112387980A true CN112387980A (en) | 2021-02-23 |
Family
ID=74603564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910765726.7A Pending CN112387980A (en) | 2019-08-19 | 2019-08-19 | Nano gold particle, drug carrier containing nano gold particle, preparation method of nano gold particle and application of nano gold particle |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112387980A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040115345A1 (en) * | 2002-07-23 | 2004-06-17 | Xueying Huang | Nanoparticle fractionation and size determination |
| US20060021468A1 (en) * | 2004-07-26 | 2006-02-02 | Ah Chil S | Gold nanoparticles and method of synthesizing the same |
| WO2011053037A2 (en) * | 2009-10-30 | 2011-05-05 | 부산대학교 산학협력단 | Method for producing gold nanoparticles |
| CN102824278A (en) * | 2011-06-17 | 2012-12-19 | 釜山大学产学协力团 | Cosmetic compostion for preventing skin aging |
| US20140377876A1 (en) * | 2013-06-19 | 2014-12-25 | Korea Basic Science Institute | Method for Preparing Size-Controlled Gold Nanoparticles and Colorimetric Detection Method of Strong Acid Using the Same |
| US20150011655A1 (en) * | 2012-06-13 | 2015-01-08 | Uniwersytet Warszawski | Flow system method for preparing substantially pure nanoparticles, nanoparticles obtained by this method and use thereof |
-
2019
- 2019-08-19 CN CN201910765726.7A patent/CN112387980A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040115345A1 (en) * | 2002-07-23 | 2004-06-17 | Xueying Huang | Nanoparticle fractionation and size determination |
| US20060021468A1 (en) * | 2004-07-26 | 2006-02-02 | Ah Chil S | Gold nanoparticles and method of synthesizing the same |
| WO2011053037A2 (en) * | 2009-10-30 | 2011-05-05 | 부산대학교 산학협력단 | Method for producing gold nanoparticles |
| CN102824278A (en) * | 2011-06-17 | 2012-12-19 | 釜山大学产学协力团 | Cosmetic compostion for preventing skin aging |
| US20150011655A1 (en) * | 2012-06-13 | 2015-01-08 | Uniwersytet Warszawski | Flow system method for preparing substantially pure nanoparticles, nanoparticles obtained by this method and use thereof |
| US20140377876A1 (en) * | 2013-06-19 | 2014-12-25 | Korea Basic Science Institute | Method for Preparing Size-Controlled Gold Nanoparticles and Colorimetric Detection Method of Strong Acid Using the Same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Seidel et al. | Green bioprinting: extrusion-based fabrication of plant cell-laden biopolymer hydrogel scaffolds | |
| Kan et al. | Formation of gold and silver nanostructures within polyvinylpyrollidone (PVP) gel | |
| CN101805606B (en) | Method for preparing monodisperse near-infrared quantum dots | |
| Patra et al. | Antibacterial, anticancer, anti-diabetic and catalytic activity of bio-conjugated metal nanoparticles | |
| Halanayake et al. | Microencapsulation of biosynthesized zinc oxide nanoparticles (ZnO-NPs) using Plumeria leaf extract and kinetic studies in the release of ZnO-NPs from microcapsules | |
| TW201330955A (en) | Manufacturing method of precious metal nanoparticles | |
| Chien et al. | Synthesis, optical properties, and sensing applications of LaF3: Yb3+/Er3+/Ho3+/Tm3+ upconversion nanoparticles | |
| WO2022234961A1 (en) | Gold nanoparticle preparation method | |
| Gang et al. | Synthesis and biological evaluation of fluorescent hyaluronic acid modified amorphous calcium phosphate drug carriers for tumor-targeting | |
| Nie et al. | Preparation and characterization of sodium alginate/phosphate-stabilized amorphous calcium carbonate nanocarriers and their application in the release of curcumin | |
| Luo et al. | Size controlled fabrication of enzyme encapsulated amorphous calcium phosphate nanoparticle and its intracellular biosensing application | |
| CN108568519B (en) | Preparation method and application of silver nano composite material | |
| Mohd Abd Ghafar et al. | Surface-functionalized cockle shell–based calcium carbonate aragonite polymorph as a drug nanocarrier | |
| Gong et al. | Engineered beads-on-a-string nanocomposites for an improved drug fast-sustained bi-stage release | |
| Huang et al. | A review of selenium (Se) nanoparticles: from synthesis to applications | |
| Mares-Briones et al. | Bimetallic Ag@ Pt core-shell nanoparticles and their catalytic activity by a green approach | |
| CN112387980A (en) | Nano gold particle, drug carrier containing nano gold particle, preparation method of nano gold particle and application of nano gold particle | |
| CN115581777B (en) | Preparation method and application of AuNC@ZIF-8 drug carrier | |
| Debnath et al. | Biocompatible polymers as a tool for the synthesis of silver nanoparticles: size tuning and in vitro cytotoxicity studies | |
| CN107625963B (en) | Nano-structured bactericidal composite medicine and preparation method thereof | |
| Thirumamagal et al. | Evaluation of the cytotoxicity effect on HAp doped with Ce2O3 and its assessment with breast cancer cell line of MCF-7 | |
| CN114948880B (en) | Preparation method of caffeic acid phenethyl ester nano stable slow release formulation | |
| CN108653239A (en) | A kind of Epigallo-catechin gallate (EGCG) nano controlled-release preparation and preparation method thereof | |
| Tian et al. | Preparation and drug-delivery study of functionalized hydroxyapatite based on natural polysaccharide gums with excellent drug-loading properties | |
| Batzli et al. | Formation of platinum-coated templates of insulin nanowires used in reducing 4-nitrophenol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |